CD274 and neoplasm: Several points related to this newly proposed method are worth mentioning: first, further studies using prospective samples are warranted to validate its feasibility in the clinic; second, whether deglycosylated PD-L1 is a consistent biomarker for various approved PD-L1 IHC diagnostic antibodies and platforms remains to be tested; third, considering the heterogeneous nature to PD-L1 expression in the tumor microenvironment, it is crucial to evaluate sample deglycosylation method in multiple sections of one patient biopsy sample.